Efeitos imediatos da oscilação extra-torácica de alta frequência "THE VESTr", em pacientes críticos submetidos a ventilação mecânica

A retenção de secreções é um problema comum em pacientes sedados e ventilados invasivamente, estas são ponto de partida para o aparecimento de infecções, pneumonia nosocomial e agravamento geral do estado clínico do paciente. Apesar de estudos comprovarem a eficácia da fisioterapia respiratória convencional nestes doentes, outros demonstraram que é cara, operador dependente, de eficácia variada e por vezes causar desconforto e dor. Vários estudos que comprovaram a segurança e eficácia da Alta Frequência Oscilatória Extra Torácica serviram de base para a realização do estudo onde se avaliou os efeitos fisiológicos imediatos da aplicação da técnica e diferenças a médio e longo prazo na comparação entre dois grupos. O VestR força o ar para dentro e para fora dos pulmões aumentando a interacção fluxo/secreções reduzindo a sua viscosidade, ao libertar e mobilizar as secreções, estas são mais facilmente aspiradas, reduzindo o risco de infecção pulmonar. Dez pacientes que cumpriram critérios de inclusão entraram no estudo. Durante dois dias foi aplicado num dos grupos o VestR durante dez minutos, três vezes por dia. Foram registados os parâmetros ventilatórios, cardíacos e de oxigenação para avaliar efeitos fisiológicos imediatos. Para comparação de grupos foram efectuados registos durante as 48h dos parâmetros referidos anteriormente. No período de follow up foram registados os dias de internamento hospitalar na unidade de cuidados intensivos e os dias de ventilação mecânica invasiva. Pelo reduzido tamanho amostral foi usada a estatística descritiva para a análise dos dados. Não foram encontradas diferenças significativas entre os dois grupos, apesar de haver uma tendência de melhoria dos parâmetros fisiológicos imediatos durante a aplicação da técnica. Concluímos que, com a limitação do tamanho amostral, os efeitos positivos imediatos da aplicação da HFCWO neste grupo podem-se revelar um bom indício para a realização de estudos futuros, com tamanhos amostrais superiores e melhor controlados, que comprovem que é uma técnica mais vantajosa e eficaz para o tratamento dos doentes críticos.

Anti-pneumoscystis carinni activitiy of primaquine imidazolidin-4-ones

Pneumocystis pneumonia (PCP) is one of the most frequent causes of mortality among HIV-infected patients. Primaquine (PQ) is an antimalarial 8-aminoquinoline effective against PCP when given in combination with clindamycin. This has drawn the attention of Medicinal Chemists towards the anti-PCP activity of 8-aminoquinolines, not only confined to those exhibiting antimalarial activity [1]. It is thought that anti-PCP 8-aminoquinolines exert their anti-PCP activity by acting on the electronic transport and redox system of the P. carinii pathogen [1]. Recently, our research group has been developing imidazolidin-4-one derivatives of PQ (Scheme 1), targeting novel compounds with improved therapeutic action, namely, higher resistance to metabolic inactivation, lower toxicity and equal or higher antimalarial activity than that of the parent drug [2,3]. These imidazolidin-4-ones were seen to block the transmission of rodent malaria, caused by Plasmodium berghei on BalbC mice, to the mosquito vector Anopheles stephensi [3]. The anti-PCP activity of our PQ derivatives is now under study and preliminary in vitro assays [4] show that some of the compounds exhibit slight to moderate activity after a 72 h incubation period against P. carinii. In one case, the IC50 was comparable to that of parent PQ. Both these studies and forthcoming results from ongoing biological assays will be presented and discussed.

Development and biological evaluation of API-ILs based on anti-bacterial and anti-fungal drugs

In recent years Ionic Liquids (ILs) are being applied in life sciences. ILs are being produce with active pharmaceutical drugs (API) as they can reduce polymorphism and drug solubility problems [1] Also ILs are being applied as a drug delivery device in innovative therapies What is appealing in ILs is the ILs building up platform, the counter-ion can be carefully chosen in order to avoid undesirable side effects or to give innovative therapies in which two active ions are paired. This work shows ILs based on ampicillin (an anti-bacterial agent) and ILs based on Amphotericin B. Also we show studies that indicate that ILs based on Ampicillin could reverse resistance in some bacteria. The ILs produced in this work were synthetized by the neutralization method described in Ferraz et. al. [2] Ampicillin anion was combined with the following organic cations 1-ethyl-3-methylimidazolium, [EMIM]; 1-hydroxy-ethyl-3-methylimidazolium, [C2OHMIM]; choline, [cholin]; tetraethylammonium, [TEA]; cetylpyridinium, [C16pyr] and trihexyltetradecylphosphonium, [P6,6,6,14]. Amphotericin B was combined with [C16pyr], [cholin] and 1-metohyethyl-3-methylimidazolium, [C3OMIM]. The ILs-APIs based on ampicillin[2] were tested against sensitive Gram-negative bacteria Escherichia coli ATCC 25922 and Klebsiella pneumonia (clinical isolated), as well as on Gram positive Staphylococcus Aureus ATCC 25923, Staphylococcus epidermidis and Enterococcus faecalis. The arising resistance developed by bacteria to antibiotics is a serious public health threat and needs new and urgent measures. We study the bacterial activity of these compounds against a panel of resistant bacteria (clinical isolated strains): E. coli CTX M9, E. coli TEM CTX M9, E. coli TEM1, E. coli CTX M2, E. coli AmpC Mox2. In this work we demonstrate that is possible to produce ILs from anti-bacterial and anti-fungal compounds. We show here that the new ILs can reverse the bacteria resistance. With the careful choice of the organic cation, it is possible to create important biological and physic-chemical properties. This work also shows that the ion-pair is fundamental in ampicillin mechanism of action.

Antibacterial activity of Ionic Liquids based on ampicillin against resistant bacteria

Antibacterial activity of novel Active Pharmaceutical Ingredient Ionic Liquids (API-ILs) based on ampicillin anion [Amp] have been evaluated. They showed growth inhibition and bactericidal properties on some sensitive bacteria and especially some Gram-negative resistant bacteria when compared to the [Na][Amp] and the initial bromide and chloride salts. For these studies were analysed the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBIC) against sensitive Gram-negative bacteria Escherichia coli ATCC 25922 and Klebsiella pneumonia (clinically isolated), as well as sensitive Gram positive S. Aureus ATCC 25923, Staphylococcus epidermidis and Enterococcus faecalis and completed using clinically isolated resistent strains: E. coli TEM CTX M9, E. coli CTX M2 and E. coli AmpC Mox. From the obtained MIC values of studied APIs-ILs and standard [Na][Amp] were derived RDIC values (relative decrease of inhibitory concentration). High RDIC values of [C16Pyr][Amp] especially against two resistant Gram-negative strains E. coli TEM CTX M9 (RDIC>1000) and E. coli CTX M2 (RDIC>100) point clearly to a potential promising role of APIs-ILs as antimicrobial drugs especially against resistant bacterial strains.